Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Atossa Therapeutics, Inc.

NASDAQ: ATOS · Life Sciences · 5 alerts · CIK 1488039

Share price
$1.93Close, Nov 16
Market cap
$19.3M
Shares outstanding
9.98MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Atossa Therapeutics, Inc. filings on SEC EDGAR ↗

8:15 AM ET 8-K
Financial Results

Atossa Therapeutics Financial Results

Atossa Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided updates on its (Z)-endoxifen clinical programs. The company highlighted a new contingent value rights (CVR) agreement that entitles shareholders to 25% of net proceeds (up to $50 million) from the potential future sale of its first FDA priority review voucher.

Term
Q3 2026

“In recent weeks, we took meaningful steps to enable shareholders to participate in potential future value from our rare disease programs. Our recently announced contingent value rights agreement entitles holders to share in 25% of the net proceeds, up to $50 million, from the sale of the first priority review voucher awarded to Atossa from its rare disease development programs. At the same time, we continued to advance (Z)-endoxifen toward several near-term milestones, including anticipated FDA clearance of our IND applications in Duchenne Muscular Dystrophy and McCune-Albright Syndrome in early 2027.”

Steven C. Quay, M.D., Ph.D., Atossa's Chairman, President and Chief Executive Officer
8:01 AM ET 10-Q
Financial Results

Atossa Therapeutics Q3 2026 Results: Net Loss of $5.64M, Loss Narrows

Atossa Therapeutics reported a net loss of $23.7 million for the nine months ended September 30, 2026, compared to $23.8 million in the prior year period. The company's cash position decreased significantly to $20.6 million, leading management to express substantial doubt about its ability to continue as a going concern without additional capital.

Key figure
Net loss $5.64M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.